Sorry, you need to enable JavaScript to visit this website.
Skip to main content
 

Search

Leaders in Pulmonary Hypertension

Leaders in Pulmonary Hypertension

 

Pulmonary Hypertension

Pulmonary Hypertension

Normal Artery in Cross Section (Magnification x100) H&E stain

NEIL DAVIE, Ph.D.

GLOBAL THERAPEUTIC AREA HEAD
PULMONARY HYPERTENSION

Neil Davie is Global Therapeutic Area Head, Pulmonary Hypertension, leading the therapeutic area’s strategy and portfolio execution, including clinical development, He has extensive experience as a drug developer leading projects across multiple therapeutic areas, particularly in specialty/rare diseases with high unmet medical need. He has held leadership roles with increased responsibility allied with strategic pharmaceutical drug development across early and late programs in the area of pulmonary, neurology, immunology and hematology.

Prior to joining Janssen in October 2019, Neil worked at UCB Pharma as Development Lead with responsibility and accountability for their innovative subcutaneous anti-FcRn monoclonal antibody platform, rozanolixizumab. Prior to this, he spent five years at Bayer as Vice President of Clinical Development responsible for the development of riociguat (Adempas) in chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH); he successfully represented Bayer at the FDA Advisory Committee, leading to the approval of Adempas in both indications. Before joining Bayer, he was Senior Medical Director in the Pulmonary Vascular Development Group at Pfizer, working on Revatio (sildenafil citrate) for PAH and additional rare diseases. Previously he was at Encysive Pharmaceuticals, where he was Director of Scientific Affairs for the launch of Thelin (sitaxentan sodium) for PAH in Europe, Australia and Canada.

Neil obtained his BSc. in Human Biology from the University of Leeds and his Ph.D. in Pulmonary Pharmacology from Imperial College London. He completed a post-doctoral fellowship at the University of Colorado Health Sciences Center (Stenmark Lab), in the field of pulmonary hypertension. He was appointed Assistant Professor of Pediatric Cardiology at the Children’s Hospital in Denver, working in the pulmonary hypertension lab of Dunbar Ivy. Previously, he held the post of Visiting Professor of Cellular & Respiratory Medicine at the University of Newcastle, working with Professor Paul Corris.

Neil Davie, Ph.D.

Global Therapeutic Area Head
Pulmonary Hypertension

SIMON EADE

HEAD, GLOBAL COMMERCIAL STRATEGY
PULMONARY HYPERTENSION

Simon Eade is Global Therapeutic Area Head of Commercial Strategy for Pulmonary Hypertension (PH). His team collaborates with the major markets to set the strategy for each brand and deliver key marketing, reimbursement, and commercial tools to ensure that brands quickly find their way to patients.

In previous roles, Simon served as Vice President and Head of the Northern European Region and Vice President and Head of the Asia Pacific Region, where he extended Actelion’s reach and the availability of its key orphan drugs across Asia (excluding Japan). Simon also led the commercial strategy development and launch for OPSUMIT® (macitentan) and VELETRI® (iv. epospotonol). He oversaw the pre-launch work on a variety of additional Actelion compounds across multiple disease areas, including UPTRAVI® (selexipag). In 2002, he helped establish the UK and Ireland affiliate where Actelion launched TRACLEER® and ZAVESCA®.

Before joining Actelion, Simon worked at both Novartis and Serono. In all, he has spent almost two decades focusing on the area of orphan drugs, helping develop awareness for conditions like pulmonary arterial hypertension (PAH), driving medical education to improve diagnosis, and finding ways to enhance access to novel therapies.

Simon Eade

Head, Global Commercial Strategy
Janssen Pulmonary Hypertension